Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Jonas Dyhrfjeld-Johnsen"'
Autor:
Raphaelle Cassel, Pierrick Bordiga, Julie Carcaud, François Simon, Mathieu Beraneck, Anne Le Gall, Anne Benoit, Valentine Bouet, Bruno Philoxene, Stéphane Besnard, Isabelle Watabe, David Pericat, Charlotte Hautefort, Axel Assie, Alain Tonetto, Jonas Dyhrfjeld-Johnsen, Jordi Llorens, Brahim Tighilet, Christian Chabbert
Publikováno v:
Disease Models & Mechanisms, Vol 12, Iss 7 (2019)
Damage to cochlear primary afferent synapses has been shown to be a key factor in various auditory pathologies. Similarly, the selective lesioning of primary vestibular synapses might be an underlying cause of peripheral vestibulopathies that cause v
Externí odkaz:
https://doaj.org/article/a61921b5ef864496b340bb8918f08e13
Publikováno v:
Frontiers in Neuroscience, Vol 3 (2009)
Studies of pathological ion channel regulation as an underlying mechanism of epilepsy have revealed alterations of the h-current in several animal models. While prior reports indicate that downregulation of the h-current is pro-excitatory on the sing
Externí odkaz:
https://doaj.org/article/fa3af21649e34b4e919d0469d2b036f9
Publikováno v:
Frontiers in Cellular Neuroscience, Vol 2 (2008)
Somatic recordings from CA1 pyramidal cells indicated a persistent upregulation of the h-current (Ih) after experimental febrile seizures. Here, we examined febrile seizure-induced long-term changes in Ih and neuronal excitability in CA1 dendrites. C
Externí odkaz:
https://doaj.org/article/77873b73ef4e489d8af470eba46b3170
Publikováno v:
Otolaryngologic Clinics of North America. 53:651-666
Despite recent, major steps forward in our understanding of tinnitus pathophysiology and improved research methodology, tinnitus remains a clear unmet clinical need. Here, the authors identify current active clinical and preclinical development progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cef78c1e35b9baee6c89facf41bb5c18
https://doi.org/10.1016/j.otc.2020.03.012
https://doi.org/10.1016/j.otc.2020.03.012
Autor:
Cindy Gueguen, Jonas Dyhrfjeld-Johnsen, Mathieu Petremann, Viviana Delgado Betancourt, Eric Wersinger
Publikováno v:
British Journal of Pharmacology. 177:623-633
Background and purpose Histamine H4 receptors are expressed in the peripheral vestibular system, and their selective inhibition improves vertigo symptoms in rats with unilateral vestibular lesions. The effects of SENS-111, a selective oral H4 recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31f95b14cf021eccdd9db6a6115635f8
https://doi.org/10.1111/bph.14803
https://doi.org/10.1111/bph.14803
Autor:
Jonas Dyhrfjeld-Johnsen, Pierre Attali
Publikováno v:
Br J Clin Pharmacol
Vertigo is associated with a wide range of vestibular pathologies. It increasingly affects the elderly, with a high cost to society. Solutions include vestibular suppressants and vestibular rehabilitation, which form the mainstay of therapy. Antihist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::865c7c2bb6f9e8c85c48e132c3ed883c
https://doi.org/10.1111/bcp.14046
https://doi.org/10.1111/bcp.14046
Autor:
Reza Rahimian, Mohammad Reza Zirak, Gohar Fakhfouri, Jonas Dyhrfjeld-Johnsen, Jean-Martin Beaulieu
Publikováno v:
Pharmacological Reviews. 71:383-412
5-HT3 receptor antagonists, first introduced to the market in the mid-1980s, are proven efficient agents to counteract chemotherapy-induced emesis. Nonetheless, recent investigations have shed light on unappreciated dimensions of this class of compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c276206979aeb3bac95fdf0fae21f4cc
https://doi.org/10.1124/pr.118.015487
https://doi.org/10.1124/pr.118.015487
Autor:
Audrey Broussy, Christophe Tran Van Ba, Jonas Dyhrfjeld-Johnsen, Sonia Poli, Charlotte Romanet, Mathieu Petremann
Publikováno v:
Otology & Neurotology. 40:254-263
HYPOTHESIS SENS-401 (R-azasetron besylate) is effective against severe acoustic trauma-induced hearing loss. BACKGROUND SENS-401 has calcineurin inhibiting properties and attenuates cisplatin-induced hearing loss in a rat model. Cisplatin-induced and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a85d5f6e26e8b652781d9c1e38d0f4ab
https://doi.org/10.1097/mao.0000000000002088
https://doi.org/10.1097/mao.0000000000002088
Publikováno v:
Otolaryngologic clinics of North America. 53(4)
Despite recent, major steps forward in our understanding of tinnitus pathophysiology and improved research methodology, tinnitus remains a clear unmet clinical need. Here, the authors identify current active clinical and preclinical development progr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::03b275862b78ae6c039577ffc1625076
https://pubmed.ncbi.nlm.nih.gov/32334870
https://pubmed.ncbi.nlm.nih.gov/32334870
Autor:
Audrey Broussy, Mathieu Petremann, Christophe Tran Van Ba, Jonas Dyhrfjeld-Johnsen, Charlotte Romanet
Publikováno v:
Otology & Neurotology. 38:1355-1361
HYPOTHESIS SENS-401, an oral clinical-stage drug, may reduce cisplatin-induced hearing loss and cochlear damage in an in vivo model. BACKGROUND Cisplatin is commonly associated with hearing loss, causing significant learning and behavioral difficulti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75fe36c006fba6e2c010f23e084cbe21
https://doi.org/10.1097/mao.0000000000001546
https://doi.org/10.1097/mao.0000000000001546